Pilot Trial to Preserve Residual Insulin Secretion in Children and Adolescents With Recent Onset Type 1 Diabetes by Using GAD-antigen (Diamyd) Therapy in Combination With Vitamin D and Ibuprofen

Trial Profile

Pilot Trial to Preserve Residual Insulin Secretion in Children and Adolescents With Recent Onset Type 1 Diabetes by Using GAD-antigen (Diamyd) Therapy in Combination With Vitamin D and Ibuprofen

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs GAD65 vaccine (Diamyd) (Primary) ; Ibuprofen; Vitamin D
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms DIABGAD; DIABGAD-1
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 19 May 2017 Status changed from active, no longer recruiting to completed.
    • 27 Mar 2017 30-month results published in a Diamyd Medical AB media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top